

Contact: Jennifer Cook Williams
Investor Relations
360-668-3701

**IMMUNOCELLULAR THERAPEUTICS ELECTS DR. NAVDEEP JAIKARIA
TO BOARD OF DIRECTORS**

Jaikaria is Former Award-Winning Analyst for Picking Biotech Stocks

LOS ANGELES, CA – June 25, 2008 – ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, announced today that Navdeep Jaikaria, Ph.D., former managing director of equity research and senior biotechnology analyst at Rodman & Renshaw, has been elected to the company’s board of directors.

“Dr. Jaikaria brings a wealth of knowledge to IMUC, and we are pleased in his eagerness to commit himself as a board member of IMUC as well, given that he was named one of the five best stock-pickers in biotechnology in the *Wall Street Journal*’s annual “Best on the Street” Analysts survey in 2007,” stated Manish Singh, Ph.D., president and chief executive officer of IMUC. “Navdeep is a strong addition to our board of directors and will be able to provide among other things, the Wall Street perspective, as we look to raise our profile with key biotechnology investors and analysts in the coming months and years.”

“I am excited to join this talented board of directors and believe that the data I have seen from IMUC’s cancer vaccines and cancer stem cell vaccines thus far, demonstrate significant potential for these drug candidates,” stated Dr. Jaikaria. “IMUC is targeting large markets with both its cancer vaccines and monoclonal antibody technologies with the hope of providing less toxic or rigorous treatment alternatives for patients with multiple types of cancer including glioblastoma, lung cancer and pancreatic cancer.”

Navdeep Jaikaria, Ph.D., brings a wide variety of experience to IMUC’s board of directors with an emphasis on the Wall Street perspective. Dr. Jaikaria recently retired from Rodman & Renshaw where he was a senior equity research analyst covering approximately 30 companies across multiple therapeutic classes. He was named one of the five best stock-pickers in biotechnology in the *Wall Street Journal*’s “Best on the Street” analysts survey in 2007. He has consistently been ranked as a top analyst and as high as number three by StarMine on the basis of portfolio returns for 2006. Dr. Jaikaria was with Rodman & Renshaw from 2003 to 2008 and held positions in equity research with Leerink Swann and Mehta Partners prior to that. Before joining Wall Street, he also served as a consultant to pharmaceutical and biotechnology companies. He has provided input to the U.S. Senate Health Committee on Biodefense issues and has been widely cited in national and international print and broadcast media including the *Wall Street Journal*, *Financial Times*, CNN and CNBC. Dr. Jaikaria holds a Ph.D. in Cell Biology and Anatomy from New York Medical College, conducted a research fellowship at The Rockefeller University and holds a B.S. in Human Biology from All India Institute of Medical Sciences.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers. IMUC's lead product candidate—a dendritic cell-based vaccine for treating brain tumors—is currently being evaluated in a Phase I clinical trial. Additionally, the company is developing a therapeutic vaccine targeting cancer stem cells for multiple cancer indications and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates; the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; the risks associated with obtaining and maintaining patent protection for vaccine and antibody product candidates and the lack of patent coverage for the differential immunization platform discovery technology; and the risk of the ability to retain and recruit senior management personnel. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###